Editas Medicine, Inc. (EDIT)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
3.16 USD
-0.10
(-3.067%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:58 a.m. EDT
The investment case for Editas Medicine is currently broken by a severe multi-year decline and deteriorating fundamentals. The stock has lost nearly 89% of its value over the last nine years, with four consecutive years of negative annual returns ending recently. This persistent downward trajectory, combined with shrinking revenues (-39% growth) and negative operating margins, signals a business struggling to execute or find product-market fit. While the balance sheet remains relatively healthy with low debt, the company is burning cash aggressively. The recent public offering and analyst downgrades confirm that the market views the current strategy as insufficient. Although the stock trades at a low absolute price, the lack of a credible turnaround story makes it a poor candidate for capital preservation. Investors should avoid this name until there is clear evidence of pipeline progress or revenue stabilization. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.084260 |
| AutoETS | 0.084260 |
| MSTL | 0.084276 |
| AutoTheta | 0.176008 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 3.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.579 |
| Excess Kurtosis | -0.65 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 392.4 |
| Revenue per Share | 0.419 |
| Market Cap | 484,939,424 |
| Forward P/E | -3.37 |
| Beta | 2.10 |
| Profit Margins | -281.59% |
| Website | https://www.editasmedicine.com |
As of July 11, 2026, 2:58 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to call volume, particularly in the near term. There is significant open interest in out-of-the-money puts (strikes below current price) expiring in late 2026 and early 2027, suggesting a bet on further downside. Conversely, call activity is concentrated at strikes significantly above the current price (5.0 and 7.5), indicating speculative hopes for a recovery but lacking immediate conviction for a near-term rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.14385962 |
| Address1 | 11 Hurley Street |
| All Time High | 99.95 |
| All Time Low | 0.91 |
| Ask | 3.92 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 3,376,910 |
| Average Daily Volume3 Month | 2,518,337 |
| Average Volume | 2,518,337 |
| Average Volume10Days | 3,376,910 |
| Beta | 2.1 |
| Bid | 2.3 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.045 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.16 |
| Current Ratio | 3.219 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.192 |
| Day Low | 3.04 |
| Debt To Equity | 392.4 |
| Display Name | Editas Medicine |
| Earnings Call Timestamp End | 1,723,032,000 |
| Earnings Call Timestamp Start | 1,723,032,000 |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,777,984,200 |
| Earnings Timestamp Start | 1,777,984,200 |
| Ebitda | -85,186,000 |
| Ebitda Margins | -2.20159 |
| Enterprise To Ebitda | -2.383 |
| Enterprise To Revenue | 5.247 |
| Enterprise Value | 203,032,848 |
| Eps Current Year | -0.9961 |
| Eps Forward | -0.93645 |
| Eps Trailing Twelve Months | -1.14 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9472 |
| Fifty Day Average Change | 0.21280003 |
| Fifty Day Average Change Percent | 0.072204135 |
| Fifty Two Week Change Percent | 14.3859625 |
| Fifty Two Week High | 4.537 |
| Fifty Two Week High Change | -1.3770001 |
| Fifty Two Week High Change Percent | -0.30350453 |
| Fifty Two Week Low | 1.66 |
| Fifty Two Week Low Change | 1.5000001 |
| Fifty Two Week Low Change Percent | 0.9036145 |
| Fifty Two Week Range | 1.66 - 4.537 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,454,509,800,000 |
| Float Shares | 79,283,528 |
| Forward Eps | -0.93645 |
| Forward P E | -3.3744462 |
| Free Cashflow | -73,816,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 87 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -1.09237 |
| Gross Profits | -42,267,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00171 |
| Held Percent Institutions | 0.49295 |
| Implied Shares Outstanding | 153,461,838 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. |
| Long Name | Editas Medicine, Inc. |
| Market | us_market |
| Market Cap | 484,939,424 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_252050056 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -108,954,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 484,172,098 |
| Number Of Analyst Opinions | 9 |
| Open | 3.19 |
| Operating Cashflow | -140,503,008 |
| Operating Margins | -8.83186 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 401 9000 |
| Previous Close | 3.26 |
| Price Eps Current Year | -3.1723723 |
| Price Hint | 4 |
| Price To Book | 70.22222 |
| Price To Sales Trailing12 Months | 12.533001 |
| Profit Margins | -2.81586 |
| Quick Ratio | 3.174 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0999999 |
| Regular Market Change Percent | -3.06748 |
| Regular Market Day High | 3.192 |
| Regular Market Day Low | 3.04 |
| Regular Market Day Range | 3.04 - 3.192 |
| Regular Market Open | 3.19 |
| Regular Market Previous Close | 3.26 |
| Regular Market Price | 3.16 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 2,066,951 |
| Return On Assets | -0.26946 |
| Return On Equity | -3.26073 |
| Revenue Growth | -0.392 |
| Revenue Per Share | 0.419 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 153,461,838 |
| Shares Percent Shares Out | 0.1464 |
| Shares Short | 22,473,029 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 15,066,130 |
| Short Name | Editas Medicine, Inc. |
| Short Percent Of Float | 0.1467 |
| Short Ratio | 8.12 |
| Source Interval | 15 |
| State | MA |
| Symbol | EDIT |
| Target High Price | 15.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 5.77778 |
| Target Median Price | 5.0 |
| Total Cash | 123,648,000 |
| Total Cash Per Share | 1.263 |
| Total Debt | 17,297,000 |
| Total Revenue | 38,693,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.14 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.697225 |
| Two Hundred Day Average Change | 0.462775 |
| Two Hundred Day Average Change Percent | 0.17157447 |
| Type Disp | Equity |
| Volume | 2,066,951 |
| Website | https://www.editasmedicine.com |
| Zip | 2,141 |